1. Field of the Invention
The present invention relates to medical devices, and more particularly to methods and apparatus for introducing fill material into a bone and for applying retraction forces to bone. An exemplary embodiment is used for applying forces to reduce a vertebral fracture.
2. Description of the Related Art
Osteoporotic fractures are prevalent in the elderly, with an annual estimate of 1.5 million fractures in the United States alone. These include 750,000 vertebral compression fractures (VCFs) and 250,000 hip fractures. The annual cost of osteoporotic fractures in the United States has been estimated at $13.8 billion. The prevalence of VCFs in women age 50 and older has been estimated at 26%. The prevalence increases with age, reaching 40% among 80-year-old women. Medical advances aimed at slowing or arresting bone loss from aging have not provided solutions to this problem. Further, the affected population will grow steadily as life expectancy increases. Osteoporosis affects the entire skeleton but most commonly causes fractures in the spine and hip. Spinal or vertebral fractures also have serious consequences, with patients suffering from loss of height, deformity and persistent pain which can significantly impair mobility and quality of life. Fracture pain usually lasts 4 to 6 weeks, with intense pain at the fracture site. Chronic pain often occurs when one level is greatly collapsed or multiple levels are collapsed.
Postmenopausal women are predisposed to fractures, such as in the vertebrae, due to a decrease in bone mineral density that accompanies postmenopausal osteoporosis. Osteoporosis is a pathologic state that literally means “porous bones”. Skeletal bones are made up of a thick cortical shell and a strong inner meshwork, or cancellous bone, of collagen, calcium salts and other minerals. Cancellous bone is similar to a honeycomb, with blood vessels and bone marrow in the spaces. Osteoporosis describes a condition of decreased bone mass that leads to fragile bones which are at an increased risk for fractures. In an osteoporotic bone, the sponge-like cancellous bone has pores or voids that increase in dimension, making the bone very fragile. In young, healthy bone tissue, bone breakdown occurs continually as the result of osteoclast activity, but the breakdown is balanced by new bone formation by osteoblasts. In an elderly patient, bone resorption can surpass bone formation thus resulting in deterioration of bone density. Osteoporosis occurs largely without symptoms until a fracture occurs.
Vertebroplasty and kyphoplasty are recently developed techniques for treating vertebral compression fractures. Percutaneous vertebroplasty was first reported by a French group in 1987 for the treatment of painful hemangiomas. In the 1990's, percutaneous vertebroplasty was extended to indications including osteoporotic vertebral compression fractures, traumatic compression fractures, and painful vertebral metastasis. In one percutaneous vertebroplasty technique, bone cement such as PMMA (polymethylmethacrylate) is percutaneously injected into a fractured vertebral body via a trocar and cannula system. The targeted vertebrae are identified under fluoroscopy. A needle is introduced into the vertebral body under fluoroscopic control to allow direct visualization. A transpedicular (through the pedicle of the vertebrae) approach is typically bilateral but can be done unilaterally. The bilateral transpedicular approach is typically used because inadequate PMMA infill is achieved with a unilateral approach.
In a bilateral approach, approximately 1 to 4 ml of PMMA are injected on each side of the vertebra. Since the PMMA needs to be forced into cancellous bone, the technique requires high pressures and fairly low viscosity cement. Since the cortical bone of the targeted vertebra may have a recent fracture, there is the potential of PMMA leakage. The PMMA cement contains radiopaque materials so that when injected under live fluoroscopy, cement localization and leakage can be observed. The visualization of PMMA injection and extravasion are critical to the technique—and the physician terminates PMMA injection when leakage is evident. The cement is injected using small syringe-like injectors to allow the physician to manually control the injection pressures.
Kyphoplasty is a modification of percutaneous vertebroplasty. Kyphoplasty involves a preliminary step that comprises the percutaneous placement of an inflatable balloon tamp in the vertebral body. Inflation of the balloon creates a cavity in the bone prior to cement injection. Further, the proponents of percutaneous kyphoplasty have suggested that high pressure balloon-tamp inflation can at least partially restore vertebral body height. In kyphoplasty, it has been proposed that PMMA can be injected at lower pressures into the collapsed vertebra since a cavity exists to receive the cement—which is not the case in conventional vertebroplasty.
The principal indications for any form of vertebroplasty are osteoporotic vertebral collapse with debilitating pain. Radiography and computed tomography must be performed in the days preceding treatment to determine the extent of vertebral collapse, the presence of epidural or foraminal stenosis caused by bone fragment retropulsion, the presence of cortical destruction or fracture and the visibility and degree of involvement of the pedicles. Leakage of PMMA during vertebroplasty can result in very serious complications including compression of adjacent structures that necessitate emergency decompressive surgery.
Leakage or extravasion of PMMA is a critical issue and can be divided into paravertebral leakage, venous infiltration, epidural leakage and intradiscal leakage. The exothermic reaction of PMMA carries potential catastrophic consequences if thermal damage were to extend to the dural sac, cord, and nerve roots. Surgical evacuation of leaked cement in the spinal canal has been reported. It has been found that leakage of PMMA is related to various clinical factors such as the vertebral compression pattern, and the extent of the cortical fracture, bone mineral density, the interval from injury to operation, the amount of PMMA injected and the location of the injector tip. In one recent study, close to 50% of vertebroplasty cases resulted in leakage of PMMA from the vertebral bodies. See Hyun-Woo Do et al., “The Analysis of Polymethylmethacrylate Leakage after Vertebroplasty for Vertebral Body Compression Fractures”, Jour. of Korean Neurosurg. Soc. Vol. 35, No. 5 (5/2004) pp. 478-82 (http://www.jkns.or.kr/htm/abstract.asp?no=0042004086).
Another recent study was directed to the incidence of new VCFs adjacent to the vertebral bodies that were initially treated. Vertebroplasty patients often return with new pain caused by a new vertebral body fracture. Leakage of cement into an adjacent disc space during vertebroplasty increases the risk of a new fracture of adjacent vertebral bodies. See Am. J. Neuroradiol. 2004 February; 25(2):175-80. The study found that 58% of vertebral bodies adjacent to a disc with cement leakage fractured during the follow-up period compared with 12% of vertebral bodies adjacent to a disc without cement leakage.
Another life-threatening complication of vertebroplasty is pulmonary embolism. See Bernhard, J. et al., “Asymptomatic diffuse pulmonary embolism caused by acrylic cement: an unusual complication of percutaneous vertebroplasty”, Ann. Rheum. Dis. 2003; 62:85-86. The vapors from PMMA preparation and injection are also cause for concern. See Kirby, B., et al., “Acute bronchospasm due to exposure to polymethylmethacrylate vapors during percutaneous vertebroplasty”, Am. J. Roentgenol. 2003; 180:543-544.
Another disadvantage of PMMA is its inability to undergo remodeling—and the inability to use the PMMA to deliver osteoinductive agents, growth factors, chemotherapeutic agents and the like. Yet another disadvantage of PMMA is the need to add radiopaque agents which lower its viscosity with unclear consequences on its long-term endurance.
In both higher pressure cement injection (vertebroplasty) and balloon-tamped cementing procedures (kyphoplasty), the methods do not provide for well controlled augmentation of vertebral body height. The direct injection of bone cement simply follows the path of least resistance within the fractured bone. The expansion of a balloon also applies compacting forces along lines of least resistance in the collapsed cancellous bone. Thus, the reduction of a vertebral compression fracture is not optimized or controlled in high pressure balloons as forces of balloon expansion occur in multiple directions.
In a kyphoplasty procedure, the physician often uses very high pressures (e.g., up to 200 or 300 psi) to inflate the balloon which first crushes and compacts cancellous bone. Expansion of the balloon under high pressures close to cortical bone can fracture the cortical bone, or cause regional damage to the cortical bone that can result in cortical bone necrosis. Such cortical bone damage is highly undesirable and results in weakened cortical endplates.
Kyphoplasty also does not provide a distraction mechanism capable of 100% vertebral height restoration. Further, the kyphoplasty balloons under very high pressure typically apply forces to vertebral endplates within a central region of the cortical bone that may be weak, rather than distributing forces over the endplate.
There is a general need to provide systems and methods for use in treatment of vertebral compression fractures that provide a greater degree of control over introduction of bone support material, and that provide better outcomes. Embodiments of the present invention meet one or more of the above needs, or other needs, and provide several other advantages in a novel and nonobvious manner.
The invention provides implant systems and methods for treatment of vertebral compression fractures, as well as systems for prophylactic treatment of osteoporotic vertebrae in patients that are susceptible to compression fractures. The invention also can be used in correcting and supporting bones in other abnormalities such as bone tumors and cysts, avascular necrosis of the femoral head and tibial plateau fractures.
In one embodiment, an apparatus and method of the invention includes introducing an open web, technical knit structure with together with a flow of PMMA bone cement into a targeted site in bone such as a vertebra. In one aspect of the invention, the knit structure will extend continuously throughout the interior of the volume of bone cement to provide reinforcing for the cured cement. In another aspect of the invention, the web openings of the knit structure are configured to allow cement flows therethrough, but the web opening dimensions have a selected nonuniform configuration to direct flows and fluid pressures of the inflowing cement to apply forces in a controlled direction for reducing a vertebral compression fracture. In any embodiment, the bone cement flows through the knit structure thus allowing cement interdigitation with the cancellous bone.
In another embodiment of the invention, the apparatus includes a technical knit structure that is coupled to an energy source to thereby heat the inflowing bone cement which is use to controllable a change the viscosity of the cement. In one embodiment, the knit structure has at least one portion that is fabricated of a conductive filament and is coupled to a radio frequency source and controller. The knit structure then can be operated in a bi-polar or mono-polar manner to controllable heat the inflowing bone cement or a selected portion thereof.
These and other objects of the present invention will become readily apparent upon further review of the following drawings and specification.
There is a general need to provide systems and methods for use in treatment of vertebral compression fractures that provide a greater degree of control over introduction of bone support material, and that provide better outcomes. The present invention meets this need and provides several other advantages in a novel and nonobvious manner.
In order to better understand the invention and to see how it may be carried out in practice, some preferred embodiments are next described, by way of nonlimiting examples only, with reference to the accompanying drawings, in which like reference characters denote corresponding features consistently throughout similar embodiments in the attached drawings.
In
Of particular interest, the first and second components 120A and 120B when combined as a composite (i) can provide an implant structure that allows for interdigitation of bone cement into cancellous bone for stabilizing micromotion to eliminate pain, (i) can provide reinforcement for the injected bone cement volume 120B to resist compression loads without fracturing even if in a thin cross-section, (iii) can be provided with nonuniform web openings 144 to direct flow of cement preferentially toward larger opening and away from smaller openings to direct forces for reducing a fracture, and (iv) can optionally provide an at least partly resorbable knit filaments to allow for eventual bone ingrowth into and throughout the cement layer or monolith.
Of particular interest, the open technical knit structure or first component 120A provides means for controlling the vectors of distraction forces caused by inflows of second component 120B (bone cement) within the first component 120A in the process of injecting and deploying the media in vertebral cancellous bone. In one aspect of the invention, the open technical knit 120A allows for the injection of bone cement to preferentially create forces that are focused for the fracture of horizontal plane 135 (
Referring to
In one embodiment as depicted in
In another embodiment similar to
In any embodiment, the flows of cement optionally can be pulsed at from 1 Hz to 1000 Hz, or preferably from 10 to 100 Hz, to provide enhanced flow characteristics for interdigitation in cancellous bone and for enhancing cement flows through the knit structure 120A. In a related method of the invention, the cement component 120B can be introduced into the knit structure 120A in different volumes wherein each volume differs in the dimension or percentage of granular materials therein to control the aggregation of such materials in open webs 144 of the knit structure 125. The infill materials can be porous scaffold materials and can include thermally insulative solid or hollow micro spheres of a glass or other material for reducing heat transfer to bone from the exothermic reaction in a typical bone cement.
In preferred embodiments, the knit reinforcing construct 120A is fabricated by technical knitting of strands, wires, filaments or the like. The fabrication also can include entangled strands as in steel wool-like or cotton ball-like materials, or woven strands or braided strands which all fall within the scope of the invention. Technical knitting machines are preferred since the machines have the ability to fabricate open strand materials that have controlled gradients in thick materials and in three dimensions. In another embodiment, an open web structure can comprise an open cell foam wherein the strands can be alternatively defined as the ligaments that surround open cells, as generally disclosed in co-pending Provisional U.S. Patent Application Ser. No. 60/605,700 filed Aug. 30, 2004 titled Vertebral Implant Constructs, Methods of Use and Methods of Fabrication, which is incorporated herein in its entirety by this reference. In other embodiments of open web filamentous structures, the structure can be provided by a fabrication process selected from the group of knitting filaments, weaving filaments, braiding filaments and entangling filaments.
In another embodiment, the knit structure 120A is fabricated of a electrically conductive metal filament and is optionally connected to an electrical energy source 150 as depicted in
In another embodiment, a knit structure 120A similar to that of
Referring to
The above description of the invention intended to be illustrative and not exhaustive. A number of variations and alternatives will be apparent to one having ordinary skills in the art. Such alternatives and variations are intended to be included within the scope of the claims. Particular features that are presented in dependent claims can be combined and fall within the scope of the invention. The invention also encompasses embodiments as if dependent claims were alternatively written in a multiple dependent claim format with reference to other independent claims.
This application is a divisional of U.S. patent application Ser. No. 11/267,950, filed Nov. 4, 2005 titled Bone Treatment Systems and Methods. U.S. patent application Ser. No. 11/267,950 claims benefit of Provisional U.S. Patent Application No. 60/625,347 filed Nov. 5, 2004 titled Systems and Methods for Treating Vertebral Fractures and also claims benefit of Provisional U.S. Patent Application No. 60/626,701 filed Nov. 10, 2004 titled Systems and Methods for Treating Vertebral Fractures. This application is related to U.S. application Ser. No. 11/165,652, filed Jun. 24, 2005, now issued as U.S. Pat. No. 7,559,932 titled Bone Treatment Systems and Methods; and U.S. patent application Ser. No. 11/165,651, filed Jun. 24, 2005, now issued as U.S. Pat. No. 7,678,116 titled Bone Treatment Systems and Methods. The entire contents of all of the above cross-referenced applications are hereby incorporated by reference in their entirety and should be considered a part of this specification.
Number | Name | Date | Kind |
---|---|---|---|
5292362 | Bass et al. | Mar 1994 | A |
5334626 | Lin | Aug 1994 | A |
5360450 | Giannini | Nov 1994 | A |
5571189 | Kuslich | Nov 1996 | A |
5648097 | Nuwayser | Jul 1997 | A |
5665122 | Kambin | Sep 1997 | A |
5676700 | Black et al. | Oct 1997 | A |
5997580 | Mastrorio et al. | Dec 1999 | A |
6129763 | Chauvin et al. | Oct 2000 | A |
6171312 | Beaty | Jan 2001 | B1 |
6231615 | Preissman | May 2001 | B1 |
6235043 | Reiley | May 2001 | B1 |
6280456 | Scribner et al. | Aug 2001 | B1 |
6309420 | Preissman | Oct 2001 | B1 |
6348679 | Ryan et al. | Feb 2002 | B1 |
6375659 | Erbe et al. | Apr 2002 | B1 |
6436140 | Liu et al. | Aug 2002 | B1 |
6436143 | Ross et al. | Aug 2002 | B1 |
6458127 | Truckai et al. | Oct 2002 | B1 |
6458375 | Gertzman et al. | Oct 2002 | B1 |
6607557 | Brosnahan et al. | Aug 2003 | B1 |
6620185 | Harvie et al. | Sep 2003 | B1 |
6622731 | Daniel et al. | Sep 2003 | B2 |
6649888 | Ryan et al. | Nov 2003 | B2 |
6740093 | Hochschuler et al. | May 2004 | B2 |
6767350 | Lob | Jul 2004 | B1 |
6790233 | Brodke et al. | Sep 2004 | B2 |
6814736 | Reiley et al. | Nov 2004 | B2 |
6835206 | Jackson | Dec 2004 | B2 |
6929640 | Underwood et al. | Aug 2005 | B1 |
6955691 | Chae et al. | Oct 2005 | B2 |
6958061 | Truckai et al. | Oct 2005 | B2 |
6979352 | Reynolds | Dec 2005 | B2 |
6985061 | Hafskjold et al. | Jan 2006 | B2 |
7014658 | Ralph et al. | Mar 2006 | B2 |
7044954 | Reiley et al. | May 2006 | B2 |
7153306 | Ralph et al. | Dec 2006 | B2 |
7186267 | Aston et al. | Mar 2007 | B2 |
7189263 | Erbe et al. | Mar 2007 | B2 |
7226481 | Kuslich | Jun 2007 | B2 |
7258700 | Lambrecht et al. | Aug 2007 | B2 |
7318823 | Sharps et al. | Jan 2008 | B2 |
7357798 | Sharps et al. | Apr 2008 | B2 |
7399739 | Shimp | Jul 2008 | B2 |
7435247 | Woloszko et al. | Oct 2008 | B2 |
7559932 | Truckai et al. | Jul 2009 | B2 |
7621952 | Truckai et al. | Nov 2009 | B2 |
7678116 | Truckai et al. | Mar 2010 | B2 |
7682378 | Truckai et al. | Mar 2010 | B2 |
7682400 | Zwirkoski | Mar 2010 | B2 |
20020026195 | Layne et al. | Feb 2002 | A1 |
20020032447 | Weikel et al. | Mar 2002 | A1 |
20020082608 | Reiley et al. | Jun 2002 | A1 |
20020099385 | Ralph et al. | Jul 2002 | A1 |
20020123750 | Eisermann et al. | Sep 2002 | A1 |
20020147497 | Belef et al. | Oct 2002 | A1 |
20020156483 | Voellmicke et al. | Oct 2002 | A1 |
20020161373 | Osorio et al. | Oct 2002 | A1 |
20020177866 | Weikel et al. | Nov 2002 | A1 |
20020183851 | Spiegelberg et al. | Dec 2002 | A1 |
20030032733 | Fisher et al. | Feb 2003 | A1 |
20030055511 | Schryver et al. | Mar 2003 | A1 |
20030069326 | Stangel et al. | Apr 2003 | A1 |
20030130373 | Walz et al. | Jul 2003 | A1 |
20030130738 | Hovda et al. | Jul 2003 | A1 |
20030199980 | Siedler | Oct 2003 | A1 |
20030220648 | Osorio et al. | Nov 2003 | A1 |
20030233096 | Osorio et al. | Dec 2003 | A1 |
20040006347 | Sproul | Jan 2004 | A1 |
20040024410 | Olson, Jr. et al. | Feb 2004 | A1 |
20040092948 | Stevens et al. | May 2004 | A1 |
20040110285 | Lendlein | Jun 2004 | A1 |
20040167561 | Boucher et al. | Aug 2004 | A1 |
20040172058 | Edwards et al. | Sep 2004 | A1 |
20040172132 | Ginn | Sep 2004 | A1 |
20040193171 | DiMauro et al. | Sep 2004 | A1 |
20040225296 | Reiss et al. | Nov 2004 | A1 |
20040228898 | Ross et al. | Nov 2004 | A1 |
20040267271 | Scribner et al. | Dec 2004 | A9 |
20050059979 | Yetkinler et al. | Mar 2005 | A1 |
20050209595 | Karmon | Sep 2005 | A1 |
20050222681 | Richley et al. | Oct 2005 | A1 |
20050245938 | Kochan | Nov 2005 | A1 |
20050251149 | Wenz | Nov 2005 | A1 |
20050261781 | Sennett et al. | Nov 2005 | A1 |
20060052743 | Reynolds | Mar 2006 | A1 |
20060052794 | McGill et al. | Mar 2006 | A1 |
20060052873 | Buck et al. | Mar 2006 | A1 |
20060074433 | McGill et al. | Apr 2006 | A1 |
20060079905 | Beyar et al. | Apr 2006 | A1 |
20060085009 | Truckai et al. | Apr 2006 | A1 |
20060085081 | Shadduck et al. | Apr 2006 | A1 |
20060089715 | Truckai et al. | Apr 2006 | A1 |
20060100635 | Reiley et al. | May 2006 | A1 |
20060106459 | Truckai et al. | May 2006 | A1 |
20060106549 | Olsson | May 2006 | A1 |
20060122621 | Truckai et al. | Jun 2006 | A1 |
20060122622 | Truckai et al. | Jun 2006 | A1 |
20060122623 | Truckai et al. | Jun 2006 | A1 |
20060122624 | Truckai et al. | Jun 2006 | A1 |
20060122625 | Truckai et al. | Jun 2006 | A1 |
20060198865 | Freyman et al. | Sep 2006 | A1 |
20060229625 | Truckai et al. | Oct 2006 | A1 |
20060264967 | Ferreyro et al. | Nov 2006 | A1 |
20060265077 | Zwirkoski | Nov 2006 | A1 |
20070162043 | Truckai et al. | Jul 2007 | A1 |
20070225705 | Osorio et al. | Sep 2007 | A1 |
20070233146 | Henniges et al. | Oct 2007 | A1 |
20070233249 | Shadduck | Oct 2007 | A1 |
20070233250 | Shadduck | Oct 2007 | A1 |
20090275995 | Truckai et al. | Nov 2009 | A1 |
Number | Date | Country |
---|---|---|
WO 0287416 | Apr 2002 | WO |
WO 2006031490 | Sep 2005 | WO |
Entry |
---|
U.S. Appl. No. 12/624,086, filed Nov. 23, 2009, Truckai, et al. |
Carrodeguas, et al., “Injectable Acrylic Bone Cements for Vertebroplasty with Improved Properties”, Journal of Biomedical Materials Research, XP002312783, vol. 68, No. 1, Jan. 15, 2004, pp. 94-104. |
B. Heublein, R. Rohde, V. Kaese, M. Niemeyer, W. Hartung, A. Haverich, “Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology?”, Heart, 2003; 89:651-656. |
Office Action in U.S. Appl. No. 11/215,730, mailed Apr. 3, 2008. |
Office Action in U.S. Appl. No. 11/215,730, mailed Jan. 23, 2009. |
Carrodeguas et al., “Injectable Acrylic Bone Cements for Vertebroplasty with Improved Properties”, Journal of Biomedical Materials Research, XP002312783, vol. 68, No. 1, Jan. 15, 2004, pp. 94-104. |
B. Heublein et al. “Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology?”, Heart 2003: 89:651-656. |
International Search Report, mailing date Jun. 20, 2006, PCT/US2005/043984, 3 pg. |
International Search Report, mailing date May 31, 2006, PCT/US2005/044055, 4 pg. |
Office Action dated Nov. 1, 2007 received in U.S. Appl. No. 11/199,582. |
Office Action dated Jan. 10, 2008 received in U.S. Appl. No. 11/146,891. |
Office Action dated Feb. 28, 2008, received in U.S. Appl. No. 11/146,893. |
Office Action dated Mar. 28, 2008 received in U.S. Appl. No. 11/267,950. |
Office Action dated Apr. 3, 2008 received in U.S. Appl. No. 11/215,730. |
Number | Date | Country | |
---|---|---|---|
20120059381 A1 | Mar 2012 | US |
Number | Date | Country | |
---|---|---|---|
60625347 | Nov 2004 | US | |
60626701 | Nov 2004 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11267950 | Nov 2005 | US |
Child | 13282653 | US |